Skip to content

ACP-PHARMA

Active
Private limited companyfounded 20251 yr activeDomentstraat 51, 1790 Affligem, BelgiumKBO/BCE: BE 1018.630.058
Summary

ACP-PHARMA has been active since 2025 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €29,290 and a net result of €24,290. The computed 12-month bankruptcy probability is 1.3% (low).

Checked score

Score 2025
Axes
Profitability100
Solvency86
Growth-
Track record67
Bankruptcy probability, 12 months
1.3% Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €2,000 at 30 days acceptable
Liquidity ample (current ratio 2.77; short-term debt: 36% and cash: 0.9% of total assets), and 39% of the assets are financed with debt.
Credit check for your own amount and term

Open the credit simulator : see how the verdict changes with amount, term and advance.

Signals

Three signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 1 year 0 10 y
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies more bankruptcies →
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 24-09-2026, 55 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 1 filing
Deviation from the deadline
2025
55 d late
← before the deadline after the deadline →
Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

On 13 January 2025, ACP-PHARMA was incorporated as a Private limited company.1 The company has filed annual accounts once, for fiscal year 2025.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2025

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, micro schema

Equity
€29,290
Total assets
€48,017
Net result
€24,290
Working capital
€30,711

Turnover and EBIT margin not published: the micro schema does not require them.

Balance-sheet composition
Equity and liabilities €48,017
Equity €29,290
Debt €18,728
Debt finances 39.0% of the balance-sheet total.
Key figures and ratios
2025 value
Current ratio
2.77
Debt to equity
0.64
ROE
82.9%
ROA
50.6%
Debt ≤ 1 year
€17,306
Income taxes
€9,520

Peer companies

Historical observation

Of the 11,279 companies that looked in July 2024 the way this one looks now, 0.7% went bankrupt within 24 months and 97% are still going.

  • Micro
  • under 2 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
0.7% went bankrupt
2.6% stopped otherwise
97% still going

A further 0.1% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a higher bankruptcy probability: 1.3% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.4%
3 0.5% 0.5%
4 0.6% 0.7%
5 0.8% 0.9%
6 1.2% 1.3%
7 1.5% 1.6%
8 1.7% 1.7%
9 2.7% 2.8%
10 5.3% 5.7%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 11,279 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 · 33 lines
Balance sheet Code2025
Assets
Total assets20/58€48,017
Current assets29/58€48,017
Amounts receivable within one year40/41€43,664
Trade receivables40€31,514
Other amounts receivable41€12,150
Cash at bank and in hand54/58€422
Deferred charges and accrued income490/1€3,932
Equity and liabilities
Total equity and liabilities10/49€48,017
Equity10/15€29,290
Contributions10/11€5,000
Reserves13€24,290
Distributable reserves133€24,290
Amounts payable17/49€18,728
Amounts payable within one year42/48€17,306
Trade debts44€6,327
Suppliers440/4€6,327
Taxes, remuneration and social security45€10,979
Taxes450/3€10,979
Accrued charges and deferred income492/3€1,422
Income statement Code2025
Other operating charges640/8€551
Gross operating margin9900€34,469
Operating profit (loss)9901€33,918
Financial income75/76B€0
Recurring financial income75€0
Financial charges65/66B€108
Recurring financial charges65€108
Profit (loss) for the period before taxes9903€33,809
Income taxes67/77€9,520
Profit (loss) for the period9904€24,290
Profit (loss) for the period to be appropriated9905€24,290
Appropriation of the result
Profit (loss) to be appropriated9906€24,290
Transfer to equity691/2€24,290
To other reserves6921€24,290

The notes to these accounts (1 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2025
Other operating charges640/8€551
Gross operating margin9900€34,469
Operating profit (loss)9901€33,918
Financial income75/76B€0
Recurring financial income75€0
Financial charges65/66B€108
Recurring financial charges65€108
Profit (loss) for the period before taxes9903€33,809
Income taxes67/77€9,520
Profit (loss) for the period9904€24,290
Profit (loss) for the period to be appropriated9905€24,290
Line2025
Assets
Total assets20/58€48,017
Current assets29/58€48,017
Amounts receivable within one year40/41€43,664
Trade receivables40€31,514
Other amounts receivable41€12,150
Cash at bank and in hand54/58€422
Deferred charges and accrued income490/1€3,932
Equity and liabilities
Total equity and liabilities10/49€48,017
Equity10/15€29,290
Contributions10/11€5,000
Reserves13€24,290
Distributable reserves133€24,290
Amounts payable17/49€18,728
Amounts payable within one year42/48€17,306
Trade debts44€6,327
Suppliers440/4€6,327
Taxes, remuneration and social security45€10,979
Taxes450/3€10,979
Accrued charges and deferred income492/3€1,422
Line2025
Profit (loss) for the period9904€24,290
Operating cash flow (approximation)€24,290

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

2026
24-09
NBB filing Annual accounts filed
fiscal year 2025 · micro schema · 55 days late
NBB filing
0 of 1 act read
About the unread acts

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Affligem · 1 establishment unit since 2025
seat establishment The establishment unit on the map
Ground area
549 m²
Building footprint
200 m²
Volume, LiDAR
863 m³
Parcel 23021A0050/00A000, Flanders · tallest building 6.7 m, ±1 floor. Linked by address, not a title deed.
1 establishment unit
ACP-PHARMA
Domentstraat 51, 1790 AffligemRetail sale of pharmaceutical products
since 20252.369.266.867
1 parcel
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
23021A0050/00A000 Flanders 548 m² 1 · 200 m² 6.7 m · 1 fl.
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Similar companies · same sector and region

The National Bank holds 1 filing for this company, but none with figures Checked can read: the latest, for fiscal year 2025, exists only as a PDF. A size comparison is therefore not possible. These companies share only the sector and the region. Of 5,220 companies in sector 47730 we hold annual accounts for 3,860. See the whole sector

Identification & contact

Identification
Legal formPrivate limited company
Founded13-01-2025
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
70200Business and other management consultancy
73300Public relations and communication consultancy
82990Other business support services
E-invoicing
Reachable via Peppol
Peppol ID 0208:1018630058
Also 9925:BE1018630058
Registered 26-02-2025

Register as of 27 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.